

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA MANUSCRIPTS PUBLISHED/ACCEPTED (2017)			
E1697	Phase III randomized study of 4 weeks of high-dose interferon- α -2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697). SS Agarwala, SJ Lee, W Yip, U Rao, A Tarhini, GI Cohen, DS Reintgen, TL Evans, J Brell, M Albertini, M Atkins, S Dakhil, R Conry, J Sosman, L Flaherty, V Sondak, WE Carson, M Smylie, A Pappo, R Kefford, J Kirkwood. <i>Journal of Clinical Oncology</i> Mar 10;35(8): 885-892, 2017. Epub 2017 Jan 30. PMID28135150; PMC5455684 https://www.ncbi.nlm.nih.gov/pubmed/28135150	10/15/02	10/27/10
E2607	A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral and vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607). K Kalinsky, S Lee, K Rubin, DP Lawrence, AJ Iafrate, DR Borger, KA Margolin, MM Leitao, Jr, AA Tarhini, HB Koon, AL Pecora, AJ Jaslawski, GI Cohen, TM Kuzel, CD Lao, JM Kirkwood. <i>Journal of Clinical Oncology</i> Jul 15;33(14):2688-2697, 2017. 2017 Mar 23 [Epub ahead of print]. PMID28334439 https://www.ncbi.nlm.nih.gov/pubmed/28334439	12/1/11	n/a
E4697	Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697). L Butterfield, F Zhao, S Lee, A Tarhini, K Margolin, R White, M Atkins, G Cohen, T Whiteside, J Kirkwood, D Lawson. <i>Clinical Cancer Research</i> Sep 1;23(17):5034-5043, 2017. May 23 [Epub ahead of print], 2017. PMID28536308; PMC5581724 https://www.ncbi.nlm.nih.gov/pubmed/28536308		
MELANOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2017)			
E1609	A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon- α 2b for resected high-risk melanoma (U.S. Intergroup E1609): preliminary safety and efficacy of the ipilimumab arms. A Tarhini, SJ Lee, FS Hodi, UNM Rao, GI Cohen, O Hamid, L Hutchins, JA Sosman, HM Kluger, VK Sondak, HB Koon, DP Lawrence, KL Kendra, DR Minor, CB Lee, MR Albertini, LE Flaherty, TM Petrella, JM Kirkwood. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), accepted, oral presentation. <i>J Clin Oncol</i> 35, (suppl; abstr 9500), 2017. http://abstracts.asco.org/199/AbstView_199_189552.html		

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2016)			
S1404	SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma. KF Grossmann, M Othus, A Tarhini, S Patel, J Moon, V Sondak, J Kirkwood, A Ribas. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), Trials in Progress, publication only. <u>J Clin Oncol</u> 34, 2016 (suppl; abstr e21032). http://abstract.asco.org/176/AbstView_176_166411.html	10/15/15	n/a
S1404	A phase III randomized trial comparing FDA approved standard of care adjuvant therapy to one year of pembrolizumab in patients with high risk resected melanoma. SWOG 1404. KF Grossmann, VK Sondak, M Othus, A Tarhini, S Patel, JM Kirkwood, A Ribas, J Moon. AACR Annual Meeting 2016, April 16-20, New Orleans, LA, poster session, abstract #CT125. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=6a4c9388-20eb-464f-98c9-810c4a933251&cKey=22d3512f-23ae-40e9-8870-a43e6635787e&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267	10/15/15	n/a

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2015)			
S0933	A phase II study of RO4929097 gamma-secretase inhibitor in metastatic melanoma: SWOG 0933. SM Lee, J Moon, BG Redman, T Chidiac, LE Flaherty, Y Zha, M Othus, A Ribas, VK Sondak, TF Gajewski, KA Margolin. <i>Cancer</i> 121(3):432-40, 2015. PMID25250858; PMC4304973 http://www.ncbi.nlm.nih.gov/pubmed/25250858	10/28/10	11/15/11
E4697	A randomized placebo-controlled phase III trial of yeast derived GM-CSF vs peptide vaccination vs GM-CSF plus peptide vaccination vs placebo in patients with "no evidence of disease" after complete surgical resection of "locally advanced" and/or stage IV melanoma: a trial of the ECOG-ACRIN cancer research group (E4697). DH Lawson, S Lee, AA Tarhini, TL Whiteside, LH Butterfield, KA Margolin, MS Ernstoff, MB Atkins, GI Cohen, JM Kirkwood. <i>Journal of Clinical Oncology</i> , Dec 1;33(34):4066-4076, 2015. PMID26351350; PMC4669592 http://www.ncbi.nlm.nih.gov/pubmed/?term=lawson+dh+yeast	3/1/02	10/31/06
Multiple*/Other	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. KF Grossmann, K Margolin. <i>Therapeutic Advances in Medical Oncology</i> May;7(3):181-191, 2015. PMID26673806;PMC4406913 [*studies S0008, S9430, S1404] http://www.ncbi.nlm.nih.gov/pubmed/26673806		
MELANOMA ABSTRACTS PUBLISHED/PRESENTED (2015)			
S1320	SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/K mutant melanoma. AP Algazi, M Othus, A Daud, JM Mehnert, CD Lao, RR Kudchadkar, KF Grossmann, R Lo, J Moon, JM Kirkwood, A Ribas, American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr TPS9093), 2015. http://abstracts.asco.org/156/AbstView_156_152593.html	7/22/14	n/a
S1404	SWOG S1404: A phase III randomized trial comparing high dose interferon to MK-3475 (pembrolizumab) in patients with high risk resected melanoma. KF Grossmann, M Othus, A Tarhini, S Patel, J Moon, V Sondak, J Kirkwood, A Ribas. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr TPS9085), 2015. http://abstracts.asco.org/156/AbstView_156_147955.html	pending activation	

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2014)			
S0008	Southwest Oncology Group S0008: A Phase III trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine DTIC, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma-An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. L Flaherty, M Othus, MB Atkins, RJ Tuthill, JA Thompson, JT Vetto, FG Haluska, A Pappo, JA. Sosman, BG Redman, J Moon, A Ribas, JM Kirkwood, VK Sondak. <u>Journal of Clinical Oncology</u> , 32(33):3771-3778, 2014. PMID25332243; PMC4226807 http://www.ncbi.nlm.nih.gov/pubmed/25332243	8/1/00	11/15/07
S9035	Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. WE Carson, JM Unger, JA Sosman, LE Flaherty, RJ Tuthill, MJ Porter, JA Thompson, RA Kempf, M Othus, A Ribas, VK Sondak. <u>Cancer Immunology Research</u> 2(10): 981-987, 2014. PMID24994597; PMC4185232 http://www.ncbi.nlm.nih.gov/pubmed/24994597	4/15/92	11/15/96
Multiple*	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. PA Ascierto, AM Grimaldi, A Carrizosa Anderson, C Bifulco, A Cochran, C Garbe, AM Eggermont, M Faries, S Ferrone, JE Gershenwald, TF Gajewski, R Halaban, FS Hodi, R Kefford, JM Kirkwood, J Larkin, S Leachman, M Maio, R Marais, G Masucci, I Melero, G Palmieri, I Puzanov, A Ribas, Y Saenger, B Schilling, B Seliger, D Stroncek, R Sullivan, A Testori, E Wang, G Ciliberto, N Mozzillo, FM Marincola, M Thurin. <u>Journal of Translational Medicine</u> , Oct 28;12(1):277, 2014. *Review of multiple group studies, including SWOG S0008 and S1404. PMID25348889; PMC4232645. http://www.ncbi.nlm.nih.gov/pubmed/25348889	n/a	n/a

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA MANUSCRIPTS PUBLISHED (2013)			
E2603	Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. KT Flaherty, S Lee, F Zhao, L Schuchter, L Flaherty, R Kefford, M Atkins, P Leming, J Kirkwood. <u>Journal of Clinical Oncology</u> 31(3):373-379, 2013. PMID:23248256; PCM Journal – In Process http://www.ncbi.nlm.nih.gov/pubmed/23248256	7/15/05	4/22/08
Multiple*	Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". PA Ascierto, AM Grimaldi, N Acquavella, L Borgognoni, L Calabrò, N Cascinelli, A Cesano, M Del Vecchio, AM Eggermont, M Faries, S Ferrone, BA Fox, TF Gajewski, J Galon, S Gnjatic, H Gogas, M Kashani-Sabet, HL Kaufman, J Larkin, RS Lo, A Mantovani, K Margolin, C Melief, G McArthur, G Palmieri, I Puzanov, A Ribas, B Seliger, J Sosman, P Suenart, AA Tarhini, G Trinchieri, F Vidal-Vanaclocha, E Wang, G Ciliberto, N Mozzillo, FM Marincola, M Thurin. <u>Journal of Translational Medicine</u> 11:137, 2013. PMID23731854;PMC3681569. *Multiple cooperative group studies including SWOG S0008 and S9348. http://www.ncbi.nlm.nih.gov/pubmed/23731854	n/a	n/a

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA MANUSCRIPTS PUBLISHED (2012)			
S0438	Randomized phase II trial of sorafenib with temsirolimus or tibifarnib in untreated metastatic melanoma (S0438). KA Margolin, J Moon, LE Flaherty, CD Lao, WL Akerley, M Othus, JA Sosman, JM Kirkwood, VK Sondak. <u>Clinical Cancer Research</u> , 18(4):1129-1137, 2012. PMID22228638; PMC3481165 http://www.ncbi.nlm.nih.gov/pubmed/22228638	8/1/07	11/15/09
S0512	Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. S Bhatia, J Moon, K Margolin, J Weber, C Lao, M Othus, A Aparicio, A Ribas, V Sondak. <u>PLoS ONE</u> 7(11):e48787, 2012. PMID23226204; PMC3511501 http://www.ncbi.nlm.nih.gov/pubmed/23226204	3/15/06	1/1/09
Multiple	New challenges in endpoints for drug development in advanced melanoma. A Ribas, P Hersey, MR Middleton, H Gogas, K Flaherty, V Sondak, JM Kirkwood. <u>Clinical Cancer Research</u> 18(2):336-341, 2012 .PMID22142824 PMC3422891 http://www.ncbi.nlm.nih.gov/pubmed?term=ribas%20a%20new%20challenges	n/a	n/a
MELANOMA ABSTRACTS PUBLISHED/PRESENTED (2012)			
S0008	Phase III trial of high dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL2 and interferon in patients with high risk melanoma (SWOG S0008): an intergroup study of CALGB, COG, ECOG and SWOG. LE Flaherty, J Moon, MB Atkins, RJ Tuthill, JA Thompson, J Vetto, FG Haluska, A Pappo, JA Sosman, B Redman, A Ribas, JM Kirkwood, VK Sondak. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 8504). http://abstract.asco.org/AbstView_114_92968.html	8/1/00	11/15/07
S0008	CNS metastases as a site of progression on SWOG inter-Group study S0008: a phase III trial of high dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high risk melanoma. W Samlowski, J Moon, M Witter, M Atkins, J Kirkwood, M Othus, A Ribas, V Sondak, L Flaherty. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 8527). http://abstract.asco.org/AbstView_114_96009.html	8/1/00	11/15/07

S0826	SWOG S0826: A phase II trial of SCH 727965 (NSC 747135) in patients with stage IV melanoma. C Lao, J Moon, J Fruehauf, L Flaherty, M Bury, A Ribas, VK Sondak. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 8521). http://abstract.asco.org/AbstView_114_95522.html	7/1/09	11/1/10
S0933	Phase II trial of RO4929097 notch gamma-secretase inhibitor in metastatic melanoma: SWOG S0933 (ClinicalTrials.gov Identifier: NCT01120275) . K Margolin, M Othus, T Gajewski, B Redman, T Chidiac, A Ribas, L Flaherty, V Sondak. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 8525). http://abstract.asco.org/AbstView_114_97400.html	10/28/10	11/15/11

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MELANOMA MANUSCRIPTS PUBLISHED/PRESENTED/ACCEPTED (2011)			
S9430	A phase II trial of complete surgical resection for stage IV melanoma: results of SWOG clinical trial S9430. JA Sosman, J Moon, RJ Tuthill, JA Warneke, JT Vetto, BG Redman, PY Liu, JM Unger, LE Flaherty, V Sondak. <u>Cancer</u> , 117:4740-4746,2011. PMID21455999; PMC3129414 http://www.ncbi.nlm.nih.gov/pubmed/21455999	11/15/96	11/15/05
MELANOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2011)			
Multiple	Benchmarks for evaluating phase II clinical trials in stage IV melanoma: the recent SWOG experience. V Sondak, M Othus, L Flaherty, B Redman, J Moon, K Margolin, C Lao, W Carson, A Ribas. International Melanoma Congress, 8 th Annual Meeting (Nov. 9-11, 2011, Tampa, FL), oral presentation, abstract 50.(studies S0026, S0438, S0508, S0512, S0855). http://flipbook.insidemoffitt.com/melanomaPresentations/friday/50%20Sondak%20benchmarks%20SONDAK%2011-11_gg.pdf	n/a	n/a

**SWOG
PUBLICATIONS LIST
MELANOMA COMMITTEE
2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MANUSCRIPTS PUBLISHED/PRESENTED (2010)			
S0331 (2660)	A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331). WE Samlowski, J. Moon, RJ Tuthill, MC Heinrich, NS Balzer-Haas, SA Merl, RC DeConti, JA Thompson, MT Witter, LE Flaherty, VK Sondak. <u>American Journal of Clinical Oncology</u> , 33(5): 495-499, 2010. PMID20019577; PMC2978644 http://www.ncbi.nlm.nih.gov/pubmed?term=samlowski%20we%20imatinib	10/1/03	3/1/07
S0508	Phase II trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. JI Clark, J Moon, LF Hutchins, JA Sosman, WM Kast, DM DaSilva, PY Liu, JA Thompson, LE Flaherty, VK Sondak. <u>Cancer</u> 116(2):424-431, 2010. PMC2811758; PMID19918923 http://www.ncbi.nlm.nih.gov/pubmed/19918923	6/1/05	1/1/07
ABSTRACTS PUBLISHED/PRESENTED (2010)			
S0008	Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from the SWOG S0008 phase III randomized adjuvant trial. VK Sondak, R Tuthill, J Moon, JA Thompson, C Lao, B Redman, LE Flaherty. Poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s(suppl;abstr 8517), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=40973	8/1/00	11/15/07
S0008	Evaluation of minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma-associated genes is a prognostic factor for survival in stage III melanoma (mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. JA Sosman, J Moon, PY Liu, L Flaherty, MC Atkins, KA Margolin, J Kirkwood, V Sondak, for SWOG and ECOG. Poster presentations, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s(suppl;abstr 8513), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=54361	8/1/00	11/15/07

*S0438	Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPi) in metastatic melanoma: Southwest Oncology Group trial S0438. K Margolin, J Moon, L Flaherty, C Lao, W Akerley, J Sosman, J Kirkwood, V Sondak. Oral presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s (suppl;abstr 8502), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=48522	8/1/07	11/15/09
*E4697	E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. DH Lawson, SJ Lee, AA Tarhini, KA Margolin, MS Ernstoff, JM Kirkwood. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); <u>Journal of Clinical Oncology</u> 28:7s, 2010 (suppl; abstr 8504); oral presentation. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=49374	3/1/02	10/31/06

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
MELANOMA COMMITTEE
2009**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MANUSCRIPTS PUBLISHED/PRESENTED (2009)			
S0331 (2660)	A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331). WE Samlowski, J. Moon, RJ Tuthill, MC Heinrich, NS Balzer-Haas, SA Merl, RC DeConti, JA Thompson, MT Witter, LE Flaherty, VK Sondak. <u>American Journal of Clinical Oncology</u> , 2009 Dec 16 [Epub ahead of print] PMID: 20019577	10/1/03	3/1/07
ABSTRACTS PUBLISHED/PRESENTED (2009)			
S0331 (2630)	A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group Study (S0331). WE Samlowski, J Moon, RJ Tuthill, MC Heinrich, NS Balzer-Haas, SA Merl, RC DeConti, JA Thompson, LE Flaherty, VK Sondak. <u>Journal of Clinical Oncology</u> 27:15s, abst. #9056, 2009.	10/1/03	3/1/07

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2008
MELANOMA COMMITTEE**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED (2008)				
9431 (2421)	Detection of copy number alterations in malignant melanoma by both a panel of 16 DNA FISH probes and array comparative genomic hybridization: a Southwest Oncology Group study (S9431). SR Moore, DL Persons, JA Sosman, D Bobadilla, V Bedell, DD Smith, SR Wolman, RJ Tuthill, J Moon, VK Sondak, ML Slovak. <u>Clinical Cancer Research</u> 14(10):2927-2935, 2008. PMID: 18483359	Melanoma	11/15/96	12/15/05
E3695 (2659)	Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. MB Atkins, J Hsu, S Lee, GI Cohen, LE Flaherty, JA Sosman, VK Sondak, JM Kirkwood. <u>Journal of Clinical Oncology</u> , 26(35):5748-5754, 2008. PMID: 19001327	Melanoma	10/15/97	4/17/02
Multiple Studies (2454)	Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. EL Korn, PY Liu, SJ Lee, JAW Chapman, D Niedzwiecki, VJ Suman, J Moon, VK Sondak, MB Atkins, EA Eisenhauer, W Parulekar, SN Markovic, S Saxman, JM Kirkwood. <u>Journal of Clinical Oncology</u> 26(4):527-534, 2008. PMID: 18235113	Melanoma	n/a	n/a
None (2577)	Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? <u>Lancet</u> 372:89-90, 2008. PMID:18620932 .	Melanoma	n/a	n/a
ABSTRACTS PUBLISHED/PRESENTED (2008)				
*S0508 (2522)	Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ), (TT), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. JI Clark, J Moon, LF Hutchins, JA Sosman, WM Kast, DM Da Silva, PY Liu, JA Thompson, V Sondak. <u>Journal of Clinical Oncology</u> , 26(15S):484s, #9007, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30355	Melanoma	6/1/05	1/1/07

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

S0026 (2384)	Evaluation of interferon alpha-2b and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. LF Hutchins, J Moon, JI Clark, JA Thompson, MK Lange, LE Flaherty, VK Sondak. <u>Cancer</u> 110(10):2269-2275, 2007.	Melanoma	11/01/01	05/01/03
-----------------	--	----------	----------	----------

ABSTRACTS PUBLISHED/PRESENTED

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

Multiple Studies (2312)	Allogeneic and autologous melanoma vaccines: where have we been and where are we going? VK Sondak, MS Sabel, JJ Mule. <u>Clinical Cancer Research</u> 12(7 Suppl):2337s-2341s, 2006.	Melanoma		
-------------------------------	--	----------	--	--

ABSTRACTS PUBLISHED/PRESENTED

9430 (2236)	Surgical resection for stage IV melanoma: a Southwest Oncology Group trial (S9430). VK Sondak, PY Liu, J Warneke, J Vetto, R Tuthill, B Redman, JA Sosman. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#8019, 2006.	Melanoma	11/15/96	11/15/05
----------------	--	----------	----------	----------

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
S9804 (2047)	A phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. RP Whitehead, J Moon, SS McCachren, EM Hersh, WE Samlowski, JT Beck, NS Tchekmedyan, VK Sondak. <u>Cancer</u> 100(8):1699-1704, 2004.	Melanoma	5/15/99	8/1/01
ABSTRACTS PUBLISHED/PRESENTED				
*9035 (2051)	Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. VK Sondak, J Sosman, JM Unger, PY Liu, J Thompson, R Tuthill, R Kempf, L Flaherty. <u>Proc of the American Society of Clinical Oncology</u> 23:707 (#7501), 2004.	Melanoma	4/15/92	11/15/96
*S0026 (2056)	Interferon alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026. L Hutchins, J Moon, J Clark, J Thompson, K Yost, V Sondak. <u>Proc of the American Society of Clinical Oncology</u> 23:713 (#7527), 2004.	Melanoma	11/1/01	5/1/03

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

ABSTRACTS PUBLISHED/PRESENTED

*9035 (2033)	HLA D3(7) confers a poor prognosis in intermediate thickness (1.5-4.0 mm) melanoma: serotyping of 553 patients on SWOG 9035. JA Sosman, J Unger, JE Lee, P Liu, L Flaherty, VK Sondak. <u>Proc of the American Society of Clinical Oncology</u> 22:710 (#2856), 2003.	Melanoma	4/15/92	11/15/96
Multiple Studies (2066)	Detection of gene copy number alterations using a panel of DNA FISH probes in Studies malignant melanoma. DL Persons, ML Slovak, JA Sosman, D Bobadilla, V Bedell, RJ Tuthill, J Moon, VK Sondak. <u>Proc of the American Association for Cancer Research</u> 44 (2 nd ed): #2510, 2003.	Melanoma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8049 (1803)	Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. RJ Tuthill, JM Unger, PY Liu, LE Flaherty, VK Sondak. <u>American Journal of Clinical Pathology</u> 118(4):504-511, 2002.	Melanoma	7/29/81	3/15/87
9035 (1747)	Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. JA Sosman, JM Unger, PY Liu, LE Flaherty, MS Park, RA Kempf, JA Thompson, PI Terasaki, VK Sondak. <u>Journal of Clinical Oncology</u> 20(8):2067-2075, 2002.	Melanoma	4/15/92	11/15/96
9035 (1689)	Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. VK Sondak, PY Liu, RJ Tuthill, RA Kempf, JM Unger, JA Sosman, JA Thompson, GR Weiss, BG Redman, JG Jakowatz, RD Noyes, LE Flaherty. <u>Journal of Clinical Oncology</u> 20(8):2058-2066, 2002.	Melanoma	4/15/92	11/15/96
9111 (1906)	Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group trial E1690. MH Chen, DP Harrington, JG Ibrahim. <u>Applied Statistics</u> 51(part 2):135-150, 2002.	Melanoma	5/15/99	6/1/00
9111 (1826)	Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group trial E1690. UNM Rao, J Ibrahim, LE Flaherty, J Richards, JM Kirkwood. <u>Journal of Clinical Oncology</u> 20(8):2053-2057, 2002.	Melanoma	5/15/99	6/1/00
9111/9512 (1922)	Letter to the Editor: Interferon alfa-2a for melanoma metastases. JM Kirkwood, JG Ibrahim, VK Sondak, MS Ernstoff, M Ross. <u>The Lancet</u> 359:978-979, 2002	Melanoma		
9325 (1920)	Editorial: How does interferon work? Does it even matter? VK Sondak. <u>Cancer</u> 95(5):947-949, 2002.	Melanoma	7/15/94	6/1/95
9325 (1825)	Immunomodulatory effects of high-dose and low-dose interferon a2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of Intergroup adjuvant trial E1690. JM Kirkwood, T Richards, HM Zarour, J Sosman, M Ernstoff, TL Whiteside, J Ibrahim, R Blum, S Wieand and R Mascari. <u>Cancer</u> 95(5):1101-1112, 2002.	Melanoma	9/15/94	5/15/95
9431	Targeting multiple genetic aberrations in isolated tumor	Melanoma	11/15/96	Open

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1845)	cells by spectral fluorescence in situ hybridization. ML Slovak, F Zhang, L Tcheurekdjian, D Bobadilla, V Bedell, DA Arber, DL Persons, JA Sosman, JL Murata-Collins. <u>Cancer Detection and Prevention</u> 26:171-179, 2002.			
9505 (1706)	A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy - a Southwest Oncology Group study. RP Whitehead, JM Unger, LE Flaherty, EH Kraut, GM Mills, CE Klein, RA Chapman, GC Doolittle, N Hammond, VK Sondak. <u>Investigational New Drugs</u> 20:105-111, 2002.	Melanoma	1/1/96	8/15/97
9512 (1978)	In reply to the letter to the editor: Sentinel-node technique will change the design of clinical trials in malignant melanoma. JM Kirkwood, SS Agarwala, J Ibrahim, J Manola, VK Sondak, MS Ernstoff, MK Ross. <u>Journal of Clinical Oncology</u> 20(8): 2209-2210, 2002.	Melanoma	7/15/96	10/15/99

ABSTRACTS PUBLISHED/PRESENTED

9035 (1785)	HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from melacine vaccine: an updated analysis of SWOG 9035. JA Sosman, JM Unger, PY Liu, R Kempf, LE Flaherty, J Thompson, VK Sondak. <u>Proc of the American Society of Clinical Oncology</u> 21:340a (#1359), 2002.	Melanoma	4/15/92	11/15/96
S9804 (1796)	Evaluation of vinorelbine tartrate (Navelbine) in patients with disseminated malignant melanoma and at least one prior systemic therapy, phase II: a Southwest Oncology Group study. J Moon, RP Whitehead, S McCachren, EM Hersh, LE Flaherty, VK Sondak. <u>Proc of the American Society of Clinical Oncology</u> 21:347a (#1386), 2002.	Melanoma	5/15/99	8/1/01

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9512 (1748)	High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup trial E1694/S9512/C509801. JM Kirkwood, JG Ibrahim, JA Sosman, VK Sondak, SS Agarwala, MS Ernstoff, U Rao. <u>Journal of Clinical Oncology</u> 19(9):2370-2380, 2001.	Melanoma	7/15/96	10/15/99
S9622 (1659)	Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy: a Southwest Oncology Group study. RP Whitehead, JM Unger, LE Flaherty, JR Eckardt, SA Taylor, MS Didolkar, W Samlowski, VK Sondak. <u>Investigational New Drugs</u> 19:239-243, 2001.	Melanoma	12/15/96	8/1/98
Multiple Studies (1578)	Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. JM Unger, LE Flaherty, PY Liu, KS Albain, VK Sondak. <u>Cancer</u> 91(6):1148-1155, 2001.	Melanoma COMMWSP		
ABSTRACTS PUBLISHED/PRESENTED				
*9035 (1760)	Significant impact of HLA class I alleles on outcome in T3NO melanoma patients treated with Melacine (MEL): an allogeneic melanoma cell lysate vaccine: prospective analysis of Southwest Oncology Group (SWOG)-9035. JA Sosman, JM Unger, P Liu, L Flaherty, R Kempf, J Thompson, V Sondak. <u>Proc of the American Society of Clinical Oncology</u> 20:351a (#1402), 2001.	Melanoma	4/15/92	11/15/96
*9111 (1907)	Pooled-analysis of four ECOG/Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma. JM Kirkwood, J Manola, J Ibrahim, VK Sondak, MS Ernstoff. <u>Proc of the American Society of Clinical Oncology</u> 20:350a (#1395), 2001.	Melanoma	5/15/91	6/1/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8393 (1688)	Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). CM Balch, SJ Soong, MI Ross, MM Urist, CP Karakousis, WJ Temple, MC Mihm, RL Barnhill, WR Jewell, HJ Wanebo, R Harrison. <u>Annals of Surgical Oncology</u> 7(2):87-97, 2000.	Melanoma	7/7/83	3/15/92
9111 (1645)	High-and low-dose interferon alfa 2b in high-risk melanoma: first analysis of Intergroup trial E16909/S9111/C9190. JM Kirkwood, J Ibrahim, VK Sondak, J Richards, LE Flaherty, MS Ernstoff, TJ Smith, U Rao, M Steele, RH Blum. <u>Journal of Clinical Oncology</u> 18(12):2444-2458, 2000.	Melanoma	5/15/91	6/1/95
Multiple Studies (1634)	Amplification and overexpression of HER-2/ <i>neu</i> are uncommon in advanced stage melanoma. DL Persons, DA Arber, JA Sosman, KA Borelli, ML Slovak. <u>Anticancer Research</u> 20:1965-1968, 2000.	Melanoma		
ABSTRACTS PUBLISHED/PRESENTED				
9035 (1621)	Adjuvant therapy with an allogeneic tumor vaccine in T3N0M0 melanoma (SWOG-9035). VK Sondak, PY Liu, RJ Tuthill, RA Kempf, JM Unger, JA Sosman, JA Thompson, GR Weiss, BG Redman, LE Flaherty. <u>Proc of the Melanoma at the Millennium</u> , pg. 79, 2000.	Melanoma	4/15/92	11/15/96
9035 (1699)	Class I HLA serotyping in T3NO melanoma patients entered onto SWOG 9035: a phase III trial of melacine TM (allogeneic tumor lysate vaccine) vs observation. JA Sosman, JM Unger, PY Liu, L Flaherty, J Thompson, V Sondak. <u>Journal of Immunotherapy</u> 23(5):605, 2000.	Melanoma	4/15/92	11/15/96
9035 (1698)	SWOG-9035: Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. VK Sondak, P-Y Liu, RJ Tuthill, RA Kempf, JM Unger, JA Sosman, JA Thompson, GR Weiss, BG Redman, JG Jakowatz, RD Noyes, LE Flaherty. <u>Journal of Immunotherapy</u> 23(5):600, 2000.	Melanoma	4/15/92	11/15/96
9111/9512 (1700)	Overview of the role of high-dose IFN(2b(HDI) in the therapy of high-risk resectable melanoma. JM Kirkwood, JA Sosman, MS Ernstoff, MA Ross, SS Agarwala, HF Edington. <u>Journal of Immunotherapy</u> 23(5):595, 2000.	Melanoma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9223 (1412)	A phase II evaluation of all <i>trans</i> -retinoic acid plus interferon alfa-2a in stage IV melanoma: A Southwest Oncology Group study. VK Sondak, PY Liu, LE Flaherty, WS Fletcher, P Periman, DR Gandara, SA Taylor, SP Balcerzak, FL Meyskens Jr. <u>Cancer Journal from Scientific American</u> 5(1):41-47, 1999.	Melanoma	10/1/93	8/15/95
ABSTRACTS PUBLISHED/PRESENTED				
*9111 (1506)	Preliminary analysis of the E1690/S9111/C9190 intergroup postoperative adjuvant trial of high- and low- dose IFNa2b (HDI and LDI) in high-risk primary or lymph node metastatic melanoma. JM Kirkwood, J Ibrahim, V Sondak, M Ernstoff, L Flaherty, T Smith, J Richards, U Rao, M Steele, R Blum. <u>Proc of the American Society of Clinical Oncology</u> 18:537a (#2072), 1999.	Melanoma	5/15/91	6/1/95
*9325 (1507)	E2690: Intergroup immunological evaluation of IFNa2b dose- response in patients (pts) with high-risk melanoma. H Zarour, T Richards, T Whiteside, J Sosman, J Ibrahim, M Ernstoff, R Blum, JM Kirkwood. <u>Proc of the American Society of Clinical Oncology</u> 18:538a (#2079), 1999.	Melanoma	7/15/94	5/15/95
9622 (1511)	Phase II trial of CI-980 in patients with disseminated malignant melanoma: A Southwest Oncology Group study. RP Whitehead, JM Unger, LE Flaherty JR Eckardt, SA Taylor, MS Didolkar, W Samlowski, VK Sondak. <u>Proc of the American Society of Clinical Oncology</u> 18:554a (#2138), 1999.	Melanoma	12/15/96	8/1/98

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8593 (1426)	Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. H Koops, M Vaglini, S Suci, BBR Kroon, JF Thompson, J Gohl, AMM Eggermont, F Di Filippo, ET Krementz, D Ruiter, FJ Lejeune. <u>Journal of Clinical Oncology</u> 16(9):2906-2912, 1998.	Melanoma	10/1/86	7/1/91
9228 (1296)	Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: A Southwest Oncology Group study. RP Whitehead, JM Unger, JW Goodwin, MJ Walker, JA Thompson, LE Flaherty, VK Sondak. <u>Journal of Immunotherapy</u> 21(6):440-446, 1998.	Melanoma	3/1/94	9/1/95
9348 (1293)	Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. KA Margolin, PY Liu, LE Flaherty, JA Sosman, MJ Walker, JW Smith III, WS Fletcher, GR Weiss, JM Unger, VK Sondak. <u>Journal of Clinical Oncology</u> 16(2):664-669, 1998.	Melanoma	4/15/94	4/15/95
Multiple Studies (1321)	Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. LE Flaherty, JM Unger, PY Liu, WC Mertens, VK Sondak. <u>American Journal of Clinical Oncology</u> 21(6):568-572, 1998.	Melanoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8049/8642 9035/9111 9512 (1325)	Adjuvant therapy for melanoma. VK Sondak, JA Wolfe. <u>Current Opinion in Oncology</u> 9:189-204, 1997.	Melanoma		
8642 (1324)	"Is interferon-g detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon-g versus observation in melanoma. VK Sondak, KJ Kopecky, JW Smith II, EM Hersh, RD Noyes, RJ Tuthill, TP Miller, LG Feun, JD Doroshow, LE Flaherty, FL Meyskens Jr. <u>Adjuvant Therapy of Cancer VIII, 1997</u> SE Salmon, eds, Lippincott-Raven Publishers 29:259-272, 1997.	Melanoma	6/1/87	5/15/90
8921 (1333)	Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. LE Flaherty, PY Liu, J Unger, VK Sondak. <u>American Journal of Clinical Oncology (CCT)</u> 20(6):600-604, 1997	Melanoma	2/15/90	9/1/90
ABSTRACTS PUBLISHED/PRESENTED				
*8593 (1297)	Treatment of in-transit melanoma metastases with tumour necrosis factor (TNF-a) and chemotherapy administered in isolated limb perfusion (ILP). F Lejeune, D Lienard, H Schraffordt Kooops, B Kroon, A Eggermont. <u>4th World Conference on Melanoma - Sydney, Australia</u> 7 Suppl 1: 848 (#167), 1997.	Melanoma	10/1/86	7/1/91
*9223 (1243)	Phase II trial of all-trans-retinoic acid (RA) plus alpha interferon (IFN) in stage IV melanoma (SWOG-9223). F Meyskens, V Sondak, PY Liu. <u>American Society of Clinical Oncology</u> 16:491a (#1768), 1997.	Melanoma	10/1/93	8/15/95
*9348 (1266)	Low antitumor activity of BCNU, DTIC, cisplatin (DDP) and tamoxifen (TAM) in advanced melanoma: a Southwest Oncology Group study. K Margolin, PY Liu, L Flaherty, J Sosman, J Unger, V Sondak. <u>American Society of Clinical Oncology</u> 16:495a (#1783), 1997.	Melanoma	4/15/94	4/15/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8393 (1188)	Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. CM Balch, S Soong, AA Bartolucci, MM Urist, CP Karakousis, TJ Smith, WJ Temple, MI Ross, WR Jewell, MC Mihm Jr, RL Barnhill, HJ Wanebo. <u>Annals of Surgery</u> 224(3):255-266, 1996.	Melanoma	7/26/83	3/15/92
8393 (1287)	Surgical therapy of primary cutaneous melanoma. PJ Geraghty, TM Johnson, VK Sondak, AE Chang. <u>Seminars in Surgical Oncology</u> 12:386-393, 1996.	Melanoma	7/7/83	3/15/92
8393 (1361)	Local recurrence in Malignant Melanoma: Long-term results of the multiinstitutional randomized surgical trial. CP Karakousis, CM Balch, MM Urist, MM Ross TJ Smith, AA Bartolucci. <u>Annals of Surgical Oncology</u> 3(5):446-452, 1996.	Melanoma	7/26/83	3/15/92
8921 (915)	The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group (SWOG-8921). LE Flaherty, PY Liu, MS Mitchell, WS Fletcher, MJ Walker, JW Goodwin, RL Stephens, VK Sondak. <u>American Journal of Clinical Oncology</u> 19(2):108-113, 1996.	Melanoma	2/15/90	9/1/90
ABSTRACTS PUBLISHED/PRESENTED				
8642 (1278)	Is interferon-y detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon-y versus observation in malignant melanoma. VK Sondak, KJ Kopecky, JW Smith II, CW Taylor, RD Noyes, RJ Tuthill, EM Hersh, LG Feun, JD Doroshow, LE Flaherty, FL Meyskens Jr. <u>Proceedings of the 8th International Conference on the Adjuvant Therapy of Cancer</u> , Scottsdale, AZ, March 14-16, p 51(#31), 1996.	Melanoma	6/1/87	5/15/90
9228 (1148)	Phase II trial of recombinant human interleukin-4 (rhIL-4) in patients with disseminated malignant melanoma: A Southwest Oncology Group (SWOG) study. RP Whitehead, J Unger, SP Balcerzak, JW Goodwin, SE Rivkin, LE Flaherty, VK Sondak. <u>American Society of Clinical Oncology</u> 15:438 (#1363), 1996.	Melanoma	3/1/94	9/1/95
*Multiple Studies (1154)	Gender differences and independent predictors of survival in patients with metastatic malignant melanoma on SWOG trials. L Flaherty, J Unger, PY Liu, K Albain, V Sondak. <u>American Society of Clinical Oncology</u> 15:433 (#1344), 1996.	Melanoma Women's Health		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8393 (1119)	A centimeter here, a centimeter there: Does it matter? TM Johnson, VK Sondak. <u>Journal of the American Academy of Dermatology</u> 33(3):532-534, 1995.	Melanoma	7/7/83	3/15/92
8642 (1042)	Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: A Southwest Oncology Group study. FL Meyskens Jr, KJ Kopecky, CW Taylor, RD Noyes, RJ Tuthill, EM Hersh, LG Feun, JH Doroshow, LE Flaherty, VK Sondak. <u>Journal of the National Cancer Institute</u> 87(22):1710-1713, 1995.	Melanoma	6/1/87	5/15/90
8913 (1104)	Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma: A Southwest Oncology Group study. M Slavik, PY Liu, EH Kraut, RB Natale, LE Flaherty, VK Sondak. <u>Investigational New Drugs</u> 13:143-147, 1995.	Melanoma	9/1/91	6/15/93
9111 (1156)	Direct visualization of the clonal progression of primary cutaneous melanoma: Application of tissue microdissection and comparative genomic hybridization. RN Wiltshire, P Duray, ML Bittner, T Visakorpi, PS Meltzer, RJ Tuthill, LA Liotta, JM Trent. <u>Cancer Research</u> 55:3954-3957, 1995.	Melanoma	5/15/91	6/1/95
9116 (1096)	A phase II trial of piroxantrone in disseminated malignant melanoma: A Southwest Oncology Group study. JA Sosman, LE Flaherty, PY Liu, W Fletcher, JA Thompson, A Hantel, V Sondak. <u>Investigational New Drugs</u> 13:83-87, 1995.	Melanoma	6/1/92	10/1/93
ABSTRACTS PUBLISHED/PRESENTED				
8049 (1082)	Tumor infiltrating lymphocytes (TILs) in stage I cutaneous melanoma: A Southwest Oncology Group study. RJ Tuthill, DJ Rector, VK Sondak, PY Liu, FL Meyskens Jr. <u>International Academy of Pathology Book of Abstracts</u> 51A (#284), 1995.	Melanoma	7/29/81	3/15/87
*8107/8118 8324/8723 8754/8804 8921 (1085)	Survival and response to treatment in patients (pts) with metastatic melanoma from intraocular primaries (MMIP) on SWOG studies. K Katato, PY Liu, V Sondak, LE Flaherty. <u>ASCO</u> 14:410 (#1298), 1995.	Melanoma		
8393 (1092)	Local recurrence in malignant melanoma: Long-term results of the surgical trial. C Karakousis, C Balch, M Urist, M Ross, T Smith, A Bartalucci. <u>Proceedings of the 48th Annual Cancer Symposium of the Society of Surgical Oncology</u> :6, 1995.	Melanoma	7/26/83	3/15/92
9116 (1086)	Phase II trial of piroxantrone in disseminated malignant melanoma: A Southwest Oncology Group study. J Sosman, PY Liu, A Hantel, L Flaherty, V Sondak. <u>ASCO</u> 14:418 (#1330), 1995.	Melanoma	6/1/92	10/1/93

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9325 (1176)	A study of the mechanism of IFN alfa-2b in high-risk melanoma in the ECOG/Intergroup trial E1690. JM Kirkwood, J Sosman, M Ernstoff, M Ross, C Gerstner, J Bryant, T Whiteside, C Johnson. <u>American Association for Cancer Research</u> 36 (#3815):641, 1995.	Melanoma	7/15/94	5/15/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8049 (993)	A randomized trial of vitamin A versus observation as adjuvant therapy in high risk stage I malignant melanoma: A Southwest Oncology Group study. FL Meyskens Jr, PY Liu, RJ Tuthill, VK Sondak, WS Fletcher, WR Jewell, W Samlowski, SP Balcerzak, JJ Costanzi, DJ Rector. <u>Journal of Clinical Oncology</u> 12(10):2060-2065, 1994.	Melanoma	7/29/81	3/15/87
8754 (916)	Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology group. VK Sondak, KJ Kopecky, PY Liu, WS Fletcher, WH Harvey, LR Laufman. <u>Anti-Cancer Drugs</u> 5:147-150, 1994.	Melanoma	1/15/89	5/1/90
ABSTRACTS PUBLISHED/PRESENTED				
8913 (964)	Phase II evaluation of merbarone in disseminated malignant melanoma: A Southwest Oncology Group study. M Slavik, PY Liu, E Kraut, R Natale, V Sondak. <u>ASCO</u> 13:398 (#1357), 1994.	Melanoma	09/01/91	06/15/93
*8921 (999)	Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility. L Flaherty, M Hussein, PY Liu, D Smith, V Sondak. <u>ASCO</u> 13:397 (#1352), 1994.	Melanoma	2/15/90	9/1/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8393 (INT-0013) (869)	Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): Results of a multi-institutional randomized surgical trial. CM Balch, MM Urist, CP Karakousis, TJ Smith, WJ Temple, K Drzewiecki, WR Jewell, AA Bartolucci, MC Mihm Jr, R Barnhill, HJ Wanebo. <u>Annals of Surgery</u> 218(3):262-269, 1993.	Melanoma	7/7/83	3/15/92
8723 (537)	Evaluation of amonafide in disseminated malignant melanoma: A Southwest Oncology Group study. M Slavik, KJ Kopecky, V Sondak, JB Craig, MK Samson. <u>IND</u> 11:223-226, 1993.	Melanoma Dev Ther	07/15/88	06/01/90
8804 (885)	Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma: A Southwest Oncology Group study. WS Fletcher, DS Daniels, VK Sondak, B Dana, R Townsend, HE Hynes, LF Hutchins, JR Pancoast. <u>AJCO</u> 16(4):359-362, 1993.	Melanoma	04/01/88	06/01/90
ABSTRACTS PUBLISHED/PRESENTED				
8921 (680)	The addition of tamoxifen (T) to dacarbazine (D) and cisplatin (C) in a Southwest Oncology Group phase II trial (8921) in metastatic malignant melanoma (MMM) stage IV. L Flaherty, PY Liu, D Daniels, V Sondak. <u>ASCO</u> 12:394 (#1349), 1993.	Melanoma	02/15/90	09/01/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

8921 (546)	Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma. Phase II Southwest Oncology Group trial. LE Flaherty, PY Liu, WS Fletcher, JW Goodwin, SP Balcerzak, D Daniels, RL Stephens, V Sondak. <u>JNCI</u> 84(11):893-894, 1992.	Melanoma	02/15/90	09/01/90
---------------	--	----------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8324 (390)	Evaluation of fludarabine phosphate in malignant melanoma. A Southwest Oncology Group study. JA Kish, K Kopecky, MA Samson, DD Von Hoff, WS Fletcher, RA Kempf, FM Muggia. <u>IND</u> 9:105-108, 1991.	Melanoma	06/15/86	08/15/88
8569 (446)	A phase II study of IV bolus recombinant interleukin-2 in advanced malignant melanoma: A Southwest Oncology Group study. RP Whitehead, KJ Kopecky, MK Samson, JJ Costanzi, RB Natale, LG Feun, EM Hersh, JJ Rinehart. <u>JNCI</u> 83(17):1250-1252, 1991.	Melanoma	08/01/86	10/01/88
ABSTRACTS PUBLISHED/PRESENTED				
*8642 (406)	A phase III trial of recombinant human interferon-gamma (IFN) as adjuvant therapy of high risk malignant melanoma (MM). FL Meyskens, Jr, K Kopecky, M Samson, D Noyes, R Tuthill, E Hersh, J Macdonald, H Jaffe, J Crowley, CA Coltman, Jr. <u>ASCO</u> 10:291 (#1019), 1991.	Melanoma	06/01/87	05/15/90
8723 (407)	Evaluation of amonafide in disseminated malignant melanoma: A Southwest Oncology Group study. M Slavik, K Kopecky, J Craig, V Sondak, M Samson. <u>ASCO</u> 10:292 (#1022), 1991.	Melanoma	07/15/88	06/01/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8049 (302)	Observation versus oral vitamin A for adjuvant treatment of stage I cutaneous melanoma. FL Meyskens, Jr, J Costanzi, K Kopecky, P Goodman. <u>Adjuvant Therapy of Cancer VI</u> , Sydney E. Salmon (Ed.), W.B. Saunders Company, pp. 593-597, 1990.	Melanoma	07/29/81	03/01/87
8562 (333)	High-dose cisplatin in disseminated melanoma: A comparison of two schedules. A Southwest Oncology Group study. JE Mortimer, S Schulman, JS Macdonald, K Kopecky, G Goodman. <u>Cancer Chemo Pharm</u> 25:373-376, 1990.	Melanoma	01/03/86	12/15/87
8642	Recombinant human interferon γ : Adverse effects in high risk stage I and II cutaneous malignant melanoma. FL Meyskens, Jr, K Kopecky, M Samson, E Hersh, J Macdonald, H Jaffe, J Crowley, CA Coltman, Jr. <u>JNCI</u> 82(12):1071, 1990.	Melanoma	06/01/87	05/15/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

*8569	A phase II study of IV bolus recombinant interleukin-2 (IL-2) in metastatic malignant melanoma: A Southwest Oncology Group study. RP Whitehead, KJ Kopecky, MK Samson, JJ Costanzi, R Natale, L Feun, EM Hersh. <u>ASCO</u> 8:284 (#1108), 1989.	Melanoma	08/01/86	10/01/88
-------	--	----------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8273	Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma: A Southwest Oncology Group study. WS Fletcher, S Green, JR Fletcher, B Dana, W Jewell, RA Townsend. <u>AJCO</u> (CCT) 11(5):589-593, 1988.	Melanoma	01/31/83	07/15/86
ABSTRACTS PUBLISHED/PRESENTED				
*8049	A randomized phase III trial of high dose vitamin A versus placebo for stage I malignant melanoma. FL Meyskens, Jr, KK Kopecky, J Costanzi, W Jewell. <u>ASCO</u> 7:247 (#955), 1988.	Melanoma	7/26/81	3/15/87
8562	High dose cisplatin in metastatic melanoma: Comparison of two schedules. JE Mortimer, J Chestnut, CS Higano, G Goodman. <u>ASCO</u> 7:254 (#985), 1988.	Melanoma	01/03/86	12/15/87

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7521	Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma. BL Trantum, D Dixon, J Quagliana, J Neidhart, SP Balcerzak, JJ Costanzi, CJ Fabian, B Neilan, T Maloney, R O'Bryan, C Groppe. <u>Cancer Treat Rep</u> 71(6):643-644, 1987.	Melanoma	11/24/75	07/29/81
8118	Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group study. DS Alberts, N Mason-Liddil, SJ Green, JD Cowan, WS Fletcher, B Neilan, JT Guy, RB Epstein. <u>Invest New Drugs</u> 5:289-292, 1987.	Melanoma	02/22/82	10/03/84
8240	Phase II evaluation of spirogermanium in malignant melanoma: A Southwest Oncology Group study. JW Goodwin, K Kopecky, M Slavik, BL Trantum, SP Balcerzak, WS Fletcher, JJ Costanzi. <u>Cancer Treat Rep</u> 71(10):985-986, 1987.	Melanoma	11/14/83	05/31/86

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

8273	Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma: A SWOG Phase II pilot study. J Fletcher, B Dana, W Jewell, R Townsend, W Fletcher. <u>ASCO</u> 5:131 (#510), 1986.	Melanoma	01/31/83	07/15/86
------	---	----------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

8065	Phase II trial of 1,4-dihydroxy-5, 8-bis((2-((2-hydroxyethyl) amino) ethyl) amino 9,10-anthracenedione dihydrochloride) (NSC 301739, DHAD) in patients with metastatic malignant melanoma. SA Taylor, BT Trantum, DD Von Hoff, JJ Costanzi. <u>Invest New Drugs</u> 3:67-69, 1985.	Melanoma	07/02/80	10/18/83
------	--	----------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7727	Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study. JJ Costanzi, WS Fletcher, SP Balcerzak, S Taylor, HJ Eyre, RM O'Bryan, M Al-Sarraf, J Frank. <u>Cancer</u> 53:833-836, 1984.	Melanoma		
7930	Vindesine in patients with metastatic malignant melanoma: A Southwest Oncology Group study. JM Quagliana, RL Stephens, LH Baker, JJ Costanzi. <u>J Clin Oncol</u> 2: 316-319, 1984.	Melanoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7963	Phase II evaluation of Amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. FR Ahmann, F Meyskens Jr, SE Jones, RM Bukowski, JH Saiers, DH Ryan, J Costanzi, CB Vaughn, CA Coltman Jr. <u>Cancer Treat Rep</u> 67:697-700, 1983.	Melanoma, Myeloma, Lymphoma, Lung, Breast		
*8108/16/ 17/18/19/ 20/61/ 8214	Southwest Oncology Group studies with Bisantrene. CA Coltman Jr, D Cowan, DD Von Hoff, GM Durie, TP Miller, E Surwit, DS Alberts, RA Shildt, F Panettiere, GM Mills, PB Wasserman, TM McDaniel. In: <u>13th International Congress of Chemotherapy</u> (Vienna, August 28-September 2, 1983). KH Spitzzy, K Karrer, eds. <u>Symposium Bisantrene</u> 213:1-4, 1983.	Myeloma, Lymphoma, GYN, GI, Melanoma, Leukemia, Sarcoma		

ABSTRACTS PUBLISHED/PRESENTED

8065	Phase II trial of Dihydroxyanthracenedione in advanced malignant melanoma: A Southwest Oncology Group study. S Taylor, D Von Hoff, F Panettiere. <u>ASCO</u> , #C-881, 1983.	Melanoma		
------	--	----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7424/25	Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: A Southwest Oncology Group study. JJ Costanzi, M Al-Sarraf, C Groppe, R Bottomley, C Fabian, J Neidhart, D Dixon. <u>Medical & Pediatric Oncology</u> 10:251-258, 1982.	Melanoma		
7730	Cisplatin hydration with and without Mannitol diuresis in refractory disseminated malignant melanoma. M Al-Sarraf, W Fletcher, N Oishi, R Pugh, JS Hewlett, L Balducci, J McCracken, F Padilla. <u>Cancer Treat Rep</u> 66:31-35, 1982.	Melanoma		
7813	Ifosfamide in the management of malignant melanoma: A Southwest Oncology Group Phase II study. JJ Costanzi, R Stephens, R O'Bryan, J Frank. <u>Seminars in Oncology</u> 9:93-95, 1982.	Melanoma		
7874	Southwest Oncology Group (SWOG) experience with Tamoxifen in metastatic melanoma. RR Reimer, J Costanzi, C Fabian. <u>Cancer Treat Rep</u> 66:1680-1681, 1982.	Melanoma		

ABSTRACTS PUBLISHED/PRESENTED

*7521	Adjuvant chemotherapy for Stage I melanoma: A Southwest Oncology Group study. B Trantum, J Frank, J Quagliana, J Costanzi. <u>ASCO</u> , #C-710, 1982.	Melanoma		
*7727/28	Chemotherapy in disseminated melanoma: A Southwest Oncology Group study. JJ Costanzi, M Al-Sarraf, J Frank. <u>ASCO</u> , #C-655, 1982.	Melanoma		
7930	Vindesine in patients with metastatic malignant melanoma. J Quagliana, R Stephens, L Baker, J Costanzi. <u>ASCO</u> , #C-707, 1982.	Melanoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7608	Sequential combination chemotherapy for disseminated melanoma: A Southwest Oncology Group study. J Costanzi, CJ Fabian, HE Wilson, DO Dixon. <u>Cancer Treat Rep</u> 65: 732-734, 1981.	Melanoma		
------	---	----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Metastatic minimal-deviation melanoma. DW Becker, CJ Miller, HB Keller. <u>Ann Plast Surg</u> 4(3):230-237, 1980.	Melanoma		
7424/25	Chemoimmunotherapy for disseminated melanoma (DM) ^a : M Al-Sarraf, JJ Costanzi, DO Dixon. In: <u>Tumor Progression: Developments in Cancer Research, Volume II</u> , 334-343, 1980.	Melanoma		
7727/28	Levamisole and chemotherapy in disseminated melanoma. M Al-Sarraf, J Costanzi, DO Dixon. In: <u>Tumor Progression: Developments in Cancer Research, Volume II</u> , 221-231, 1980.	Melanoma		
7764	Baker's Antifol in combination with 5-Fluorouracil (5-FU) and Methyl CCNU in treatment of metastatic colorectal cancer: A Southwest Oncology Group study (Protocol 7764). M Shaw, J Bonnet, H Wilson, L Heilbrun. <u>Cancer Treat Rep</u> 64:247-250, 1980.	Melanoma		
ABSTRACTS PUBLISHED/PRESENTED				
7521	Adjuvant chemotheapy with BCNU, Hydrea and DTIC (BHD) with or without immunotherapy (BCG) in high-risk melanoma patients. A Southwest Oncology Group study. J Quagliana, B Trantum, J Neidhart, R Gagliano. <u>ASCO</u> , #C-316, 1980.	Melanoma		
7727/28	Chemoimmunotherapy for disseminated melanoma (DM): A Southwest Oncology Group study. JJ Costanzi, M Al-Sarraf, DO Dixon. <u>ASCO</u> , #C-610, 1980.	Melanoma		
7963	A broad Phase II trial of AMSA with <u>in vitro</u> stem cell culture drug sensitivity correlation. F Ahmann, F Meyskens, S Jones, B Durie, D Alberts, S Salmon. <u>ASCO</u> , #C-199, 1980.	Breast, Lung, Lymphoma, Melanoma, Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7520	Phase II trial of Dianhydrogalactitol in metastatic malignant melanoma. A Southwest Oncology Group study. JT Thigpen, M Al-Sarraf, JS Hewlett. <u>Cancer Treat Rep</u> 63(4):525-528, 1979.	Melanoma		
------	---	----------	--	--

ABSTRACTS PUBLISHED/PRESENTED

7424	Chemoimmunotherapy for disseminated melanoma. J Costanzi, M Al-Sarraf, D Dixon. <u>ASCO</u> , #C-293, 1979.	Melanoma		
7730	The clinical trial of Cis-Platinum hydration with and without Mannitol in patients with previously treated advanced malignant melanoma. M Al-Sarraf. <u>AACR</u> , #746, 1979.	Melanoma		
7764	Baker's Antifol (BAF) in combination with Methyl-CCNU and 5-FU after the treatment of metastatic colorectal cancer. MT Shaw, LK Heilbrun. <u>ASCO</u> , #C-33, 1979.	Melanoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7424/25	Chemotherapy and BCG in treatment of disseminated malignant melanoma. JJ Costanzi. In: <u>Immunotherapy of Cancer Present Status of Trials in Man</u> , pp. 87-93, 1978.	Melanoma		
7504	Cycloctidine chemotherapy for malignant melanoma. E McKelvey, J Hewlett, T Thigpen, J Whitecar. <u>Cancer Treat Rep</u> 62(3):469-471.	Melanoma		
7506	Piperazinedione in patients with advanced malignant melanoma. M Al-Sarraf, T Thigpen, CW Groppe, A Haut, F Padilla. <u>Cancer Treat Rep</u> 62(7):1101-1103, 1978.	Melanoma		

ABSTRACTS PUBLISHED/PRESENTED

7424/25	Value of cellular mediating immunity in patients with disseminated melanoma treated with chemoimmuno-therapy. M Al-Sarraf, J Costanzi. <u>AACR</u> (#49), 1978.	Melanoma		
7424/25	Prognostic value of pre-therapy total peripheral lymphocytes and white blood cells in patients with advanced malignant melanoma. M Al-Sarraf, J Costanzi. <u>ASCO</u> (#C-15), 1978.	Melanoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

436/9	Combination chemotherapy with bis chloroethyl nitrosourea (BCNU), vincristine and dimethyl triazeno imidazole carboxamide (DTIC) in disseminated malignant melanoma. EM McKelvey, JK Luce, RW Talley, EM Hersh, JS Hewlett and TE Moon. <u>Cancer</u> 39:1-4, 1977.	Melanoma		
965	Bis chloroethyl nitrosourea, vincristine, dimethyl triazeno imidazole carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. EM McKelvey, JK Luce, VK Vaitkevicius, TW Talley, GP Bodey, M Lane and TE Moon. <u>Cancer</u> 39:5-10, 1977.	Melanoma		

ABSTRACTS PUBLISHED/PRESENTED

7424/25	Chemotherapy and BCG in the treatment of disseminated melanoma: A Southwest Oncology Group study. JJ Costanzi. <u>AACR</u> , #455, 1977.	Melanoma		
---------	--	----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

*7424/5	Combination chemoimmunotherapy for disseminated malignant melanoma (DMM). JJ Costanzi. <u>ASCO</u> , #C-18, 1976.	Melanoma		
---------	---	----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1973**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

434	Intraarterial infusion therapy with 5-(3,3-dimethyl-1-triazeno)imidazole 4-carboxamide (NSC-45388) for malignant melanoma. L Einhorn, C McBride, JK Luce, E Caioli, JA Gottlieb. <u>Cancer</u> 32:749-755, 1973.	Melanoma		
-----	--	----------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1972**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Treatment of malignant melanoma with camptothecin. JA Gottlieb and JK Luce. <u>Cancer Chemotherapy Reports</u> 56:103-105, 1972.	Melanoma		
?	An evaluation of the management of patients with cerebral metastases from malignant melanoma. JA Gottlieb, E Frei III and JK Luce. <u>Cancer</u> 29:701-705, 1972.	Melanoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1971**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Chemotherapy of malignant melanoma with intra-arterial infusions of dimethyl imidazole triazeno carboxamide (NSC-45388). JA Gottlieb and JK Luce. <u>Clinical Research</u> 19:491, 1971.	Melanoma		
968	Dose schedule with hydroxyurea (NSC-32065) in malignant melanoma. JA Gottlieb, E Frei III and JK Luce. <u>Cancer Chemotherapy Reports</u> 55(3):277-280, 1971.	Melanoma		